CD83 Antibody (HB15a): sc-19677

CD83 Antibody (HB15a) is a mouse monoclonal IgG2b kappa light chain antibody that detects CD83 protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). CD83 Antibody (HB15a) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CD83 is a heavily glycosylated membrane protein belonging to the immunoglobulin superfamily, primarily expressed in mature dendritic cells, Langerhans cells, and interdigitating reticulum cells within lymphoid tissues. CD83 plays a crucial role in immune response regulation, particularly in the activation and maturation of dendritic cells, which are essential for initiating T cell responses against pathogens and tumors. Structurally, CD83 features an extracellular V-type immunoglobulin-like domain, a single transmembrane domain, and a 40-residue cytoplasmic tail, which are important for its function in cell signaling and adhesion. CD83 has been identified as a sialic acid-binding immunoglobulin-like lectin (Siglec) adhesion molecule, facilitating interactions between dendritic cells and monocytes as well as CD8+ T cells, thereby enhancing the immune response. CD83 expression serves as a marker for mature antigen-presenting dendritic cells, which are pivotal in generating tumor-specific T cell immunity, making CD83 a significant target for anti-cancer vaccine development.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD83 Antibody (HB15a) References:

1. CD83 is an I-type lectin adhesion receptor that binds monocytes and a subset of activated CD8+ T cells [corrected].  |  Scholler, N., et al. 2001. J Immunol. 166: 3865-72. PMID: 11238630
2. Dendritic cells injected via different routes induce immunity in cancer patients.  |  Fong, L., et al. 2001. J Immunol. 166: 4254-9. PMID: 11238679
3. Induction of human tumor-loaded dendritic cells.  |  Berger, CL., et al. 2001. Int J Cancer. 91: 438-47. PMID: 11251964
4. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily.  |  Zhou, LJ., et al. 1992. J Immunol. 149: 735-42. PMID: 1378080
5. Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality.  |  Holtan, SG., et al. 2023. Clin Cancer Res. 29: 1114-1124. PMID: 36622700
6. CD83 Regulates the Immune Responses in Inflammatory Disorders.  |  Riaz, B., et al. 2023. Int J Mol Sci. 24: PMID: 36769151
7. CD83 expression characterizes precursor exhausted T cell population.  |  Wu, Z., et al. 2023. Commun Biol. 6: 258. PMID: 36906640
8. Microglial expression of CD83 governs cellular activation and restrains neuroinflammation in experimental autoimmune encephalomyelitis.  |  Sinner, P., et al. 2023. Nat Commun. 14: 4601. PMID: 37528070
9. Soluble CD83 modulates human-monocyte-derived macrophages toward alternative phenotype, function, and metabolism.  |  Peckert-Maier, K., et al. 2023. Front Immunol. 14: 1293828. PMID: 38162675
10. Subtractive cDNA cloning of a novel member of the Ig gene superfamily expressed at high levels in activated B lymphocytes.  |  Kozlow, EJ., et al. 1993. Blood. 81: 454-61. PMID: 8422464
11. The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells.  |  Lechmann, M., et al. 2001. J Exp Med. 194: 1813-21. PMID: 11748282
12. Overexpression, purification, and biochemical characterization of the extracellular human CD83 domain and generation of monoclonal antibodies.  |  Lechmann, M., et al. 2002. Protein Expr Purif. 24: 445-52. PMID: 11922761

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CD83 Antibody (HB15a) has 21 citations in a variety of scientific publications.

Primary antibodies like Anti-CD83 Antibody (HB15a) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CD83 Antibody (HB15a) Specifications

Alternate Product Name: CD83

Product Clone Name: HB15a

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids:

Epitope Target: CD83

Epitope Species: human

Product Reactivity/Detection: CD83

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), FCM

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 21 citations in various scientific publications

Available Conjugates/Forms for CD83 Antibody (HB15a): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, L: Azide-Free, PE: Phycoerythrin